Colinz Laboratories Ltd.
Snapshot View

24.05 +0.85 ▲3.7%

30 July 2021, 04:00:00 P.M.
Volume: 1,604

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.findoc-cll.in
Financial Indicators
Market Cap 10.99 Cr.
Earnings per share (EPS) 0.52 Trailing Twelve Months Ending 2021-06
Price-Earning Ratio (PE) 46.39 Trailing Twelve Months Ending 2021-06
Industry PE 35.15 Trailing Twelve Months Ending 2021-06
Book Value / Share 18.38 Trailing Twelve Months Ending 2021-06
Price to Book Value 1.31 Calculated using Price: 24.05
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.46 Cr. 4,571,000 Shares
FaceValue 10
Company Profile

Colinz Laboratories was established in 1987, the company is having modern manufacturing facility near Mumbai. The company is equipped with a full fledged in house testing / quality control laboratory.

The company houses well experienced pharmacists / technical personnel in development dept / manufacturing and caters to an ethical promotion of specialty products in India.

The company is having a well experienced marketing team of over 300 personnels and is having expertise in turn key projects (Design, erection & commissioning of pharma formulation plants) Transfer of technical know how (Pilot Batch to Commercial productions).

Business area of the company spreads to:

Pharmaceutical Formulations (of all dosages forms)

  • Tablets
  • Capsules
  • Parenterals
  • Creams/ Ointments/Lotions
  • Dry Powder
  • Liquid Orals
  • Soft Gelatine Capsules

Therapeutic Segments

  • Anti Biotics & Anti Bacterials
  • Anti Hypertensives
  • Diuretics
  • Lipid lowering Agents (Cholestrole Reducers)
  • Anti Emetics etc.

Vetinary formulations

  • Feed mix
  • Bolus
  • Vitamins & Others

Nutraceuticals

  • Spirulina
  • Co enzyme Q10 
  • Clucosamine
  • Lecithin
  • Vitamins

Herbal Preparations

  • Pain Balm (Instant relief for all types of pain)
  • Anti Cold Rub 

Ayurvedic Skin Care Creams Treatment of

  • Pimples 
  • Fairness
  • Stretch Marks 
  • Cracks

Capsules/Tablets/ Creams/ Powders

  • Anti Piles
  • Laxatives
  • Anti Diabetic
  • Anti Hypertensive
  • Antacid
  • Vigour & Vitality
  • General Debility 

Contract Manufacturing & Technical Know How Product Development

- Product Development & Clinical Research - Technical know how for formulations  - Currently Manufacturing for Europeon & Japanese companies

Sourcing API& / Intermediates Turn key products 

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+3.66%
1 Week
+2.34%
1 Month
+0.54%
3 Month
+94.74%
6 Month
+132.59%
1 Year
+200.62%
2 Year
+177.39%
5 Year
+140.50%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 1.81 1.28 1.06 1.55 1.52 2.21 3.48 1.79 1.91
Return on Capital Employed (%) 3.18 4.24 2.52 3.12 3.27 3.12 3.25 3.45 3.30
Return on Assets (%) 1.08 0.80 0.67 0.94 0.93 1.45 2.39 1.30 1.45

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 6 6 6 6 6 7 7 7 7
Non Curr. Liab. 3 3 2 3 2 1 1 1 0
Curr. Liab. 1 1 1 2 1 2 2 2 2
Minority Int.
Equity & Liab. 10 10 10 11 10 10 10 9 9
Non Curr. Assets 6 6 6 5 4 4 4 4 3
Curr. Assets 4 4 4 6 5 5 6 6 6
Misc. Exp. not W/O
Total Assets 10 10 10 11 10 10 10 9 9

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 7 7 7 8 8 8 8 8 8
Other Income 0 0 0 0 0 0 0 0 0
Total Income 7 7 8 8 8 8 8 8 8
Total Expenditure -6 -7 -7 -7 -8 -8 -8 -7 -7
PBIDT 1 1 0 1 1 1 0 0 0
Interest 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0
Taxation 0 0 0 0 0 0 0 0 0
Exceptional Items
PAT 0 0 0 0 0 0 0 0 0

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 0 0 1 0 1 0 0 0 1
Cash Fr. Inv. 0 0 0 0 0 0
Cash Fr. Finan. 0 0 0 0 -1 0 0 0 0
Net Change 0 0 0 1 0 0 0 0 1
Cash & Cash Eqvt 1 1 1 2 2 2 2 2 3

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 36.31 36.31 36.42 36.42 36.42 36.42 36.42 36.42 36.42
Public 63.69 63.69 63.58 63.58 63.58 63.58 63.58 63.58 63.58
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Sat, 31 Jul 2021
Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed herewith Newspaper Clippings of Audited Financial Results for the Quarter and year ended on 30th June 2021 published in FREE PRESS JOURNAL and NAVSHAKTI on 31st July 2021 in pursuance of Regulation 47(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 which were approved in the Board meeting held on 30th July 2021.
Fri, 30 Jul 2021
Board Meeting Outcome for Sub: Outcome Of The Board Meeting<BR> BSE Code: 531210<BR>
The Meeting of Board of Directors was held on Friday 30th July 2021 at 03:30 p.m. The Board of Directors discussed and/or approved the following:

1. The Board considered and approved Un-Audited Financial Results for the quarter ended 30th June 2021 as per Regulation 33 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. In this regard the Statutory Auditors have carried out Limited Review of the above results.
Please find enclosed copy of unaudited financial results along with Limited Review Report for the quarter ended 30th June 2021.
Fri, 30 Jul 2021
Sub: Outcome Of The Board Meeting<BR> BSE Code: 531210<BR>
The Meeting of Board of Directors was held on Friday 30th July 2021 at 03:30 p.m. The Board of Directors discussed and/or approved the following:

1. The Board considered and approved Un-Audited Financial Results for the quarter ended 30th June 2021 as per Regulation 33 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. In this regard the Statutory Auditors have carried out Limited Review of the above results.
Please find enclosed copy of unaudited financial results along with Limited Review Report for the quarter ended 30th June 2021.

Technical Scans View Details

Fri, 30 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index
Both SRS And ARS Above Zero Both SRS And ARS Above Zero

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,708.53 774.00 +10.1%
Divi's Laboratories Ltd. 129,702.64 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 78,400.54 4,712.70 +0.9%
Cipla Ltd. 74,235.31 920.30 +4.3%
Cadila Healthcare Ltd. 59,986.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 57,873.32 4,025.00 -0.3%
Aurobindo Pharma Ltd. 53,701.27 916.50 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 63.95 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.13 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 30.87 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 28.12 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 384.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.07 916.50 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.00 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.95 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 4.05 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.62 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.60 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.45 916.50 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 0.18 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 916.50 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 10.09 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 916.50 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 12.53 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 916.50 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 17,131.99 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 916.50 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 1,546.98 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 916.50 +0.9%